Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
January 24, 2024 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic...
SENISCA appoints Dr. Sarah Cole as Chief Executive Officer
November 02, 2023 03:00 ET
|
Senisca Ltd
SENISCA appoints Dr. Sarah Cole as Chief Executive Officer Exeter, UK — 02 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and...
DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT 45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer
October 29, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics,...
Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and a New President of DRGT Research
October 21, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings, Ltd (DRGT), Ltd a clinical stage specialty pharmaceutical company, announced the appointment of Lynne Powell...
DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99)
September 18, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New...
DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure
July 15, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...
C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline
June 25, 2019 02:00 ET
|
C4X Discovery Holdings PLC
C4X Discovery Holdings plc (“C4XD”, “C4X Discovery” or the “Company”) C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline 25 June 2019 – C4X...
DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor
June 10, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...
Auransa to Participate in BioCentury's 26th Annual Future Leaders in the Biotech Industry Conference
April 08, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development
February 05, 2019 03:22 ET
|
Druggability Technologies Holdings Ltd
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced the expansion of the clinical team, with the addition of Dr. Elizabeth Manning Duus, who has been named...